Journal
NEUROLOGY
Volume 79, Issue 2, Pages 170-174Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e31825f06c3
Keywords
-
Categories
Funding
- INSERM through the French Dystonia Network
- MERZ-Pharma
- Djillali Mehri
- Lundbeck
- Teva
- Novartis
- Boeringher-Ingelheim
- Abbott Products
- Direction Generale de l'Organisation des soins (DGOS)
- Institut National de la Sante et de la Recherche Medicale (INSERM)
- Michael J. Fox Foundation for Parkinson Research
- French association for Essential Tremor (APTES)
- UCB Pharma
- Swiss National Foundation
- French Ministry of Research
- ARSla charity
- DHOS-INSERM
- ANR (French National Institutes)
- AMADYS
- Alliance France Dystonie (patients' associations)
- French Agency for Research
- Programme Hospitalier de Recherche Clinique
- Michael J. Fox Foundation
- French Association Against Myopathies (non-profit foundations)
- INSERM (COSSEC)
- AP-HP (DRC-PHRC)
- Fondation pour la Recherche Medicale
- Dystonia Coalition (Pilot project)
- IPSEN
- TEVA Pharma
- Dystonia Coalition
- Dystonia Medical Research Foundation
- Movement Disorders Society
- World Federation of Neurology Association of Parkinsonism and Related Disorders
- Bachmann and Strauss Foundation
Ask authors/readers for more resources
Objective: Paroxysmal kinesigenic dyskinesia (PKD) is a rare disorder characterized by recurrent attacks of hyperkinetic movements. PKD can be isolated or associated with benign infantile seizures as part of the infantile convulsions with choreoathetosis (ICCA) syndrome. Mutations in the PRRT2 gene were recently identified in patients with PKD and ICCA. We studied the prevalence of PRRT2 mutations and characteristics of the patients in a European population of patients with PKD and ICCA. Methods: Patients were recruited through the 1996-2011 database of our DNA bank, to which physicians refer DNA with a putative diagnosis and clinical information. Two movement disorders experts reviewed the information on patients with a putative diagnosis of PKD. Patients who fulfilled the criteria for PKD and ICCA were included. The PRRT2 coding sequence was analyzed by direct sequencing. Results: Among 42 index cases of unrelated families referred with a putative diagnosis of PKD, a total of 34 patients, including 32 with isolated PKD and 2 with ICCA, were selected for genetic analysis. Mutations introducing premature termination codons were identified in 22 of 34 patients including 13 of 14 families and 9 of 20 patients with sporadic cases. The previously described c.649dupC/pArg217ProfsX8 and c.629dupC/pAla211SerfsX14 were present, respectively, in 17 patients and 1 patient; we also report 3 novel mutations: c.649delC/pArg217GlufsX12 in 2 patients, and c.562C>T/pGln188X and c. 649C>T/pArg217X, each in 1 patient. The group with mutations was characterized by a younger age at onset (9 years) compared with the patients without mutations (15 years; p < 0.01). Conclusion: Mutations in PRRT2 are a major cause of PKD in familial and sporadic cases in the European population. Neurology (R) 2012;79:170-174
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available